Imotun is developed by Chong Kun Dang Pharmaceutical.

What development phase is Imotun in?

Imotun is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Imotun

Chong Kun Dang Pharmaceutical · FDA-approved active Small molecule Quality 8/100

At a glance

Generic name	Imotun
Also known as	Avocado-Soya Unsaponifiables 300.03mg/Cap
Sponsor	Chong Kun Dang Pharmaceutical
Drug class	Biological modulator
Target	Specific signaling molecules
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Pipeline indications

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee (PHASE4)
The Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Imotun CI brief — competitive landscape report
Imotun updates RSS · CI watch RSS
Chong Kun Dang Pharmaceutical portfolio CI